Bicycle Therapeutics (BCYC) PT Lowered to $42 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- S&P Global explores potential separation of Capital IQ business
- SpaceX stock drops amid spaceport lawsuit, debt concerns
Rodman & Renshaw Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
February 25, 2025 9:45 AM ESTRodman & Renshaw analyst Tony Butler reiterated a Buy rating and $33.00 price target on Bicycle Therapeutics (NASDAQ: BCYC)
The analyst comments "Bicycle Therapeutics plc (BCYC; Buy) provided its 4Q24 and FY2024 business updates this morning before the markets opened. Recall that Bicycles clinical pipeline consists of Bicycle-Toxin Conjugates (BTC) and Bicycle-radio conjugates (BRC) against solid tumors.... More



